Somatostatin and Neuropeptide Y in Cerebrospinal Fluid: Correlations With Amyloid Peptides Aβ1–42 and Tau Proteins in Elderly Patients With Mild Cognitive Impairment

• Main Authors: Emmanuelle Duron, Jean-Sébastien Vidal, Dominique Grousselle, Audrey Gabelle, Sylvain Lehmann, Florence Pasquier, Stéphanie Bombois, Luc Buée, Bernadette Allinquant, Susanna Schraen-Maschke, Christiane Baret, Anne-Sophie Rigaud, Olivier Hanon, Jacques Epelbaum
• Format: Article
• Language: English
• Published: Frontiers Media S.A. 2018-10-01
• Series: Frontiers in Aging Neuroscience
• Subjects: somatostatin; neuropeptide Y; peptides Aβ1–42; tau proteins; cerebrospinal fluid; mild cognitive impairment
• Online Access: https://www.frontiersin.org/article/10.3389/fnagi.2018.00297/full

A combination of low cerebrospinal fluid (CSF) Amyloid β1–42 (Aβ1–42) and high Total-Tau (T-Tau) and Phosphorylated-Tau (P-Tau) occurs at a prodromal stage of Alzheimer’s disease (AD) and recent findings suggest that network abnormalities and interneurons dysfunction contribute to cognitive deficits. Somatostatin (SOM) and Neuropeptide Y (NPY) are two neuropeptides which are expressed in GABAergic interneurons with different fates in AD the former only being markedly affected. The aim of this study was to analyze CSF SOM, NPY and CSF Aβ1–42; T-Tau, P-Tau relationships in 43 elderly mild cognitively impairment (MCI) participants from the Biomarker of AmyLoïd pepTide and AlZheimer’s disease Risk (BALTAZAR) cohort. In these samples, CSF SOM and CSF Aβ1–42 on the one hand, and CSF NPY and CSF T-Tau and P-Tau on the other hand are positively correlated. CSF SOM and NPY concentrations should be further investigated to determine if they can stand for early AD biomarkers.Clinical Trial Registration: www.ClinicalTrials.gov, identifier #NCT01315639.